or Try an Advanced Search...

    Technical Analysis for NRBO - NeuroBo Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 3.93 2.34% 0.09
    NRBO closed up 2.34 percent on Wednesday, May 8, 2024, on 16 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Its advance stalled at its 200 day moving average, an important long-term support / resistance line. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    Earnings due: May 10
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical NRBO trend table...
    Date Alert Name Type % Chg
    200 DMA Resistance Bearish 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    NR7 Range Contraction 0.00%
    Weak + Overbought Other 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Weak, Overbought and Reversal Signs Reversal 0.00%
    Gapped Up Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Older End-of-Day Signals for NRBO ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 about 17 hours ago
    Possible Inside Day about 17 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    Rose Above 200 DMA about 20 hours ago
    Gap Up Closed about 21 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    NRBO Chart by TradingView
    Basic chart:

    Profile

    Researches and develops disease-modifying therapies for neurodegenerative diseases
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biology Organ Systems Neuroscience Stem Cell Neurodegenerative Diseases Degenerative Disease Neurodegeneration Senescence

    Is NRBO a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 30 NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June
    Apr 23 NRBO: First Patient Dosed in Phase 1 Trial of DA-1726 for the Treatment of Obesity…
    Apr 12 NeuroBo Pharmaceuticals files for $150M mixed shelf
    Apr 1 NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
    Mar 28 NeuroBo Pharmaceuticals GAAP EPS of -$2.46
    Mar 28 NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
    Mar 13 NeuroBo Phase 2a study for MASH drug to proceed as planned
    Mar 13 NeuroBo Pharmaceuticals Receives Safety Review Committee Approval to Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
    Mar 4 NeuroBo Pharmaceuticals appoints Marshall Woodworth as CFO
    Mar 4 NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive Marshall Woodworth as Chief Financial Officer
    See more NRBO news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.7499
    52 Week Low 2.8888
    Average Volume 122,070
    200-Day Moving Average 3.99
    50-Day Moving Average 4.18
    20-Day Moving Average 3.45
    10-Day Moving Average 3.54
    Average True Range 0.27
    RSI (14) 58.51
    ADX 21.76
    +DI 27.98
    -DI 15.46
    Chandelier Exit (Long, 3 ATRs) 3.23
    Chandelier Exit (Short, 3 ATRs) 3.79
    Upper Bollinger Bands 4.01
    Lower Bollinger Band 2.90
    Percent B (%b) 0.93
    BandWidth 32.30
    MACD Line -0.06
    MACD Signal Line -0.18
    MACD Histogram 0.1248
    Fundamentals Value
    Market Cap 19.07 Million
    Num Shares 4.85 Million
    EPS -43.82
    Price-to-Earnings (P/E) Ratio -0.09
    Price-to-Sales 0.00
    Price-to-Book 1.03
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 4.17
    Resistance 3 (R3) 4.17 4.08 4.13
    Resistance 2 (R2) 4.08 4.02 4.09 4.12
    Resistance 1 (R1) 4.01 3.98 3.97 4.01 4.10
    Pivot Point 3.92 3.92 3.90 3.93 3.92
    Support 1 (S1) 3.85 3.86 3.81 3.85 3.76
    Support 2 (S2) 3.76 3.82 3.77 3.74
    Support 3 (S3) 3.69 3.76 3.73
    Support 4 (S4) 3.69